ID   RIPK3_RAT               Reviewed;         478 AA.
AC   Q9Z2P5; B0BMV6;
DT   02-MAY-2002, integrated into UniProtKB/Swiss-Prot.
DT   19-FEB-2014, sequence version 3.
DT   02-OCT-2024, entry version 168.
DE   RecName: Full=Receptor-interacting serine/threonine-protein kinase 3 {ECO:0000305};
DE            EC=2.7.11.1;
DE   AltName: Full=Homocysteine respondent protein HCYP2 {ECO:0000303|PubMed:15057822};
DE   AltName: Full=RIP-like protein kinase 3 {ECO:0000250|UniProtKB:Q9QZL0};
DE   AltName: Full=Receptor-interacting protein 3 {ECO:0000250|UniProtKB:Q9QZL0};
DE            Short=RIP-3 {ECO:0000250|UniProtKB:Q9QZL0};
GN   Name=Ripk3 {ECO:0000312|RGD:628899};
GN   Synonyms=Rip3 {ECO:0000250|UniProtKB:Q9QZL0};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Wistar Kyoto;
RA   Chen K.H., Tang J.;
RT   "A homocysteine-respondent gene cloned from WKY VSMCs by differential
RT   display.";
RL   Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Spleen;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Serine/threonine-protein kinase that activates necroptosis
CC       and apoptosis, two parallel forms of cell death. Necroptosis, a
CC       programmed cell death process in response to death-inducing TNF-alpha
CC       family members, is triggered by RIPK3 following activation by ZBP1.
CC       Activated RIPK3 forms a necrosis-inducing complex and mediates
CC       phosphorylation of MLKL, promoting MLKL localization to the plasma
CC       membrane and execution of programmed necrosis characterized by calcium
CC       influx and plasma membrane damage. In addition to TNF-induced
CC       necroptosis, necroptosis can also take place in the nucleus in response
CC       to orthomyxoviruses infection: following ZBP1 activation, which senses
CC       double-stranded Z-RNA structures, nuclear RIPK3 catalyzes
CC       phosphorylation and activation of MLKL, promoting disruption of the
CC       nuclear envelope and leakage of cellular DNA into the cytosol. Also
CC       regulates apoptosis: apoptosis depends on RIPK1, FADD and CASP8, and is
CC       independent of MLKL and RIPK3 kinase activity (By similarity).
CC       Phosphorylates RIPK1: RIPK1 and RIPK3 undergo reciprocal auto- and
CC       trans-phosphorylation (By similarity). In some cell types, also able to
CC       restrict viral replication by promoting cell death-independent
CC       responses. In response to flavivirus infection in neurons, promotes a
CC       cell death-independent pathway that restricts viral replication:
CC       together with ZBP1, promotes a death-independent transcriptional
CC       program that modifies the cellular metabolism via up-regulation
CC       expression of the enzyme ACOD1/IRG1 and production of the metabolite
CC       itaconate. Itaconate inhibits the activity of succinate dehydrogenase,
CC       generating a metabolic state in neurons that suppresses replication of
CC       viral genomes (By similarity). RIPK3 binds to and enhances the activity
CC       of three metabolic enzymes: GLUL, GLUD1, and PYGL. These metabolic
CC       enzymes may eventually stimulate the tricarboxylic acid cycle and
CC       oxidative phosphorylation, which could result in enhanced ROS
CC       production (By similarity). {ECO:0000250|UniProtKB:Q9QZL0,
CC       ECO:0000250|UniProtKB:Q9Y572}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000250|UniProtKB:Q9QZL0};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000250|UniProtKB:Q9QZL0};
CC   -!- ACTIVITY REGULATION: Activity is stimulated by ZBP1, which senses
CC       double-stranded Z-RNA structures. RIPK3-dependent necroptosis is
CC       inhibited by RIPK1: RIPK1 prevents the ZBP1-induced activation of RIPK3
CC       via FADD-mediated recruitment of CASP8, which cleaves RIPK1 and limits
CC       TNF-induced necroptosis. {ECO:0000250|UniProtKB:Q9QZL0}.
CC   -!- SUBUNIT: Interacts (via RIP homotypic interaction motif) with RIPK1
CC       (via RIP homotypic interaction motif); this interaction induces RIPK1
CC       phosphorylation and formation of a RIPK1-RIPK3 necrosis-inducing
CC       complex. Interacts with MLKL; the interaction is direct and triggers
CC       necroptosis. Interacts with ZBP1 (via RIP homotypic interaction motif);
CC       interaction with ZBP1 activates RIPK3, triggering necroptosis (By
CC       similarity). Upon TNF-induced necrosis, the RIPK1-RIPK3 dimer further
CC       interacts with PGAM5 and MLKL; the formation of this complex leads to
CC       PGAM5 phosphorylation and increase in PGAM5 phosphatase activity. Binds
CC       TRAF2 and is recruited to the TNFR-1 signaling complex. Interacts with
CC       PYGL, GLUL and GLUD1; these interactions result in activation of these
CC       metabolic enzymes. Interacts with BIRC2/c-IAP1, BIRC3/c-IAP2 and
CC       XIAP/BIRC4. Interacts with ARHGEF2 (By similarity). Interacts with
CC       PELI1 (via atypical FHA domain); the phosphorylated form at Thr-185
CC       binds preferentially to PELI1 (By similarity). Interacts with BUB1B,
CC       TRAF2 and STUB1 (By similarity). Interacts with CASP6 (By similarity).
CC       Component of the AIM2 PANoptosome complex, a multiprotein complex that
CC       drives inflammatory cell death (PANoptosis) (By similarity).
CC       {ECO:0000250|UniProtKB:Q9QZL0, ECO:0000250|UniProtKB:Q9Y572}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000250|UniProtKB:Q9QZL0}. Nucleus {ECO:0000250|UniProtKB:Q9QZL0}.
CC       Note=Mainly cytoplasmic. Present in the nucleus in response to
CC       influenza A virus (IAV) infection. {ECO:0000250|UniProtKB:Q9QZL0}.
CC   -!- DOMAIN: The RIP homotypic interaction motif (RHIM) mediates interaction
CC       with the RHIM motif of RIPK1. Both motifs form a hetero-amyloid
CC       serpentine fold, stabilized by hydrophobic packing and featuring an
CC       unusual Cys-Ser ladder of alternating Ser (from RIPK1) and Cys (from
CC       RIPK3). {ECO:0000250|UniProtKB:Q9Y572}.
CC   -!- PTM: RIPK1 and RIPK3 undergo reciprocal auto- and trans-
CC       phosphorylation. Autophosphorylated following interaction with ZBP1.
CC       Phosphorylation of Ser-201 plays a role in the necroptotic function of
CC       RIPK3. Autophosphorylates at Thr-228 and Ser-229 following activation
CC       by ZBP1: phosphorylation at these sites is a hallmark of necroptosis
CC       and is required for binding MLKL. Phosphorylation at Thr-185 is
CC       important for its kinase activity, interaction with PELI1 and for its
CC       ability to mediate TNF-induced necroptosis (By similarity).
CC       {ECO:0000250|UniProtKB:Q9Y572}.
CC   -!- PTM: Polyubiquitinated with 'Lys-48' and 'Lys-63'-linked chains by
CC       BIRC2/c-IAP1 and BIRC3/c-IAP2, leading to activation of NF-kappa-B.
CC       Ubiquitinated by STUB1 leading to its subsequent proteasome-dependent
CC       degradation. {ECO:0000250|UniProtKB:Q9Y572}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF036537; AAD02059.2; -; mRNA.
DR   EMBL; AABR06083269; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH474049; EDM14285.1; -; Genomic_DNA.
DR   EMBL; CH474049; EDM14286.1; -; Genomic_DNA.
DR   EMBL; BC158580; AAI58581.1; -; mRNA.
DR   RefSeq; NP_647558.1; NM_139342.1.
DR   AlphaFoldDB; Q9Z2P5; -.
DR   SMR; Q9Z2P5; -.
DR   IntAct; Q9Z2P5; 1.
DR   MINT; Q9Z2P5; -.
DR   STRING; 10116.ENSRNOP00000027759; -.
DR   GlyGen; Q9Z2P5; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9Z2P5; -.
DR   PhosphoSitePlus; Q9Z2P5; -.
DR   PaxDb; 10116-ENSRNOP00000027759; -.
DR   GeneID; 246240; -.
DR   KEGG; rno:246240; -.
DR   UCSC; RGD:628899; rat.
DR   AGR; RGD:628899; -.
DR   CTD; 11035; -.
DR   RGD; 628899; Ripk3.
DR   VEuPathDB; HostDB:ENSRNOG00000020465; -.
DR   eggNOG; KOG0192; Eukaryota.
DR   HOGENOM; CLU_559689_0_0_1; -.
DR   InParanoid; Q9Z2P5; -.
DR   OrthoDB; 2968576at2759; -.
DR   TreeFam; TF106506; -.
DR   Reactome; R-RNO-2562578; TRIF-mediated programmed cell death.
DR   Reactome; R-RNO-3295583; TRP channels.
DR   Reactome; R-RNO-5213460; RIPK1-mediated regulated necrosis.
DR   Reactome; R-RNO-5675482; Regulation of necroptotic cell death.
DR   Reactome; R-RNO-937041; IKK complex recruitment mediated by RIP1.
DR   PRO; PR:Q9Z2P5; -.
DR   Proteomes; UP000002494; Chromosome 15.
DR   Proteomes; UP000234681; Chromosome 15.
DR   Bgee; ENSRNOG00000020465; Expressed in spleen and 18 other cell types or tissues.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; ISO:RGD.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0004672; F:protein kinase activity; ISS:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; ISO:RGD.
DR   GO; GO:0032147; P:activation of protein kinase activity; ISS:UniProtKB.
DR   GO; GO:1990000; P:amyloid fibril formation; ISS:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; ISO:RGD.
DR   GO; GO:0051607; P:defense response to virus; ISS:UniProtKB.
DR   GO; GO:0097528; P:execution phase of necroptosis; ISS:UniProtKB.
DR   GO; GO:0048535; P:lymph node development; ISS:UniProtKB.
DR   GO; GO:0070266; P:necroptotic process; ISS:UniProtKB.
DR   GO; GO:0097527; P:necroptotic signaling pathway; ISO:RGD.
DR   GO; GO:0038061; P:non-canonical NF-kappaB signal transduction; ISO:RGD.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; ISO:RGD.
DR   GO; GO:0060545; P:positive regulation of necroptotic process; ISS:UniProtKB.
DR   GO; GO:0090312; P:positive regulation of protein deacetylation; ISO:RGD.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; ISO:RGD.
DR   GO; GO:0097300; P:programmed necrotic cell death; ISO:RGD.
DR   GO; GO:0072593; P:reactive oxygen species metabolic process; ISO:RGD.
DR   GO; GO:0046006; P:regulation of activated T cell proliferation; ISS:UniProtKB.
DR   GO; GO:0070235; P:regulation of activation-induced cell death of T cells; ISS:UniProtKB.
DR   GO; GO:0002819; P:regulation of adaptive immune response; ISS:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:2000452; P:regulation of CD8-positive, alpha-beta cytotoxic T cell extravasation; ISS:UniProtKB.
DR   GO; GO:2000377; P:regulation of reactive oxygen species metabolic process; ISO:RGD.
DR   GO; GO:0001914; P:regulation of T cell mediated cytotoxicity; ISS:UniProtKB.
DR   GO; GO:0032649; P:regulation of type II interferon production; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   GO; GO:0048536; P:spleen development; ISS:UniProtKB.
DR   GO; GO:0033077; P:T cell differentiation in thymus; ISS:UniProtKB.
DR   GO; GO:0043029; P:T cell homeostasis; ISS:UniProtKB.
DR   GO; GO:0048538; P:thymus development; ISS:UniProtKB.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR025735; RHIM_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR050167; Ser_Thr_protein_kinase.
DR   PANTHER; PTHR23257:SF985; RECEPTOR-INTERACTING SERINE_THREONINE-PROTEIN KINASE 3; 1.
DR   PANTHER; PTHR23257; SERINE-THREONINE PROTEIN KINASE; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF12721; RHIM; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Apoptosis; ATP-binding; Cytoplasm; Kinase; Methylation; Necrosis;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN           1..478
FT                   /note="Receptor-interacting serine/threonine-protein kinase
FT                   3"
FT                   /id="PRO_0000086612"
FT   DOMAIN          22..290
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          311..330
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          362..429
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           437..461
FT                   /note="RIP homotypic interaction motif (RHIM)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y572"
FT   COMPBIAS        373..402
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        409..429
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        143
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         28..36
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         51
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         2
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZL0"
FT   MOD_RES         165
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZL0"
FT   MOD_RES         185
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y572"
FT   MOD_RES         201
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y572"
FT   MOD_RES         228
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZL0"
FT   MOD_RES         229
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y572"
FT   MOD_RES         254
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZL0"
FT   MOD_RES         301
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZL0"
FT   MOD_RES         323
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZL0"
FT   MOD_RES         335
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZL0"
FT   MOD_RES         350
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZL0"
FT   MOD_RES         369
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZL0"
FT   MOD_RES         380
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZL0"
FT   MOD_RES         392
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZL0"
FT   MOD_RES         474
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZL0"
FT   CONFLICT        153
FT                   /note="P -> L (in Ref. 1; AAD02059)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   478 AA;  52218 MW;  87C83BFD16287136 CRC64;
     MSSVKLWLNG ASSISLVGSE ELENLGFVGK GGFGAVFRAR HTAWNLDVAV KIVNSKKISR
     EVKAMVNLRH ENVLLLLGVT ENLEWDYVYG PALVTGFMEN GSLSGLLQPS CPRPWPLLCR
     LLEEVVLGMC YLHSLNPSLL HRDLKPSNVL LDPELHAKLA DFGLSTFQGG SQSGSGSGSR
     DSGGTLAYLA PELLDNDGKA SKASDVYSFG VLVWTVLAGR EAEVVDKTSL IRGAVCNRQR
     RPPLTELPPD SPETPGLEGL KELMTHCWSS EPKDRPSFQD CESKTNNVYI LVQDKVDAAV
     SKVKHYLSQY RSSDTKLSAR ESSQKGTEVD CPRETIVYEM LDRLHLEEPS GSVPERLTSL
     TERRGKEASF GHATPAGTSS DTLAGTPQIP HTLPSRGTTP RPAFTETPGP DPQRNQGDGR
     NSNPWYTWNA PNPMTGLQSI VLNNCSEVQI GQHNCMSVQP RTAFPKKEPA QFGRGRGW
//
